Literature DB >> 15142119

Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.

Tetsuya E Tanimoto1, Takuhiro Yamaguchi, Yuji Tanaka, Akiko Saito, Kinuko Tajima, Takahiro Karasuno, Masanobu Kasai, Kenji Kishi, Takehiko Mori, Nobuo Maseki, Satoko Morishima, Shigesaburo Miyakoshi, Masaharu Kasai, Yuju Ohno, Sung-Won Kim, Akihiko Numata, Masahiro Kami, Yoichi Takaue, Shin-ichiro Mori, Mine Harada.   

Abstract

A reduced incidence of graft versus host disease (GvHD) has been documented among Japanese allogeneic bone marrow transplantation (BMT) patients, as the Japanese are genetically more homogeneous than western populations. To clarify whether this ethnic difference affects the results of allogeneic peripheral blood stem cell transplantation (PBSCT), we conducted a nationwide survey to compare clinical outcomes of allogeneic PBSCT (n = 214) and BMT (n = 295) from a human leucocyte antigen-identical-related donor in Japanese patients. The cumulative incidence of grades II-IV acute GvHD was 37.4% for PBSCT and 32.0% for BMT. The cumulative incidence of extensive chronic GvHD at 1 year was significantly higher after PBSCT than BMT (42% vs. 27%; P < 0.01). The organ involvement patterns of GvHD were different between the two groups. By multivariate analyses, the incidence of chronic GvHD was significantly increased in PBSCT, whereas the stem cell source did not affect the incidence of acute GvHD, transplant-related mortality, relapse or survival. We concluded that Japanese PBSCT patients have an increased risk of chronic GvHD compared with BMT patients, but the incidence of acute GvHD was still lower than in western populations. Thus, the choice of haematopoietic stem cell source should be considered based on data for individual ethnic populations.

Entities:  

Mesh:

Year:  2004        PMID: 15142119     DOI: 10.1111/j.1365-2141.2004.04943.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Authors:  Xia Qin; Yi-Ping Zhu; Cheng-Juan Luo; Ming Zhou; Ke Huang; Chun Chen; Wei-Ping Zhang; Yuan Sun; Rong-Mu Luo; Xiang-Feng Tang; Ting Yang; Xian-Min Song; Shao-Yan Hu; Zi-Min Sun; Jiong Hu; Shun-Qing Wang; Jing Chen
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

2.  Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry.

Authors:  Koji Nagafuji; Keitaro Matsuo; Takanori Teshima; Shin-ichiro Mori; Hisashi Sakamaki; Michihiro Hidaka; Hiroyasu Ogawa; Yoshihisa Kodera; Yoshinobu Kanda; Atsuo Maruta; Takehiko Mori; Fumiaki Yoshiba; Tatsuo Ichinohe; Masanobu Kasai; Yoshifusa Takatsuka; Kohmei Kubo; Hiroshi Sao; Yoshiko Atsuta; Ritsuro Suzuki; Takashi Yoshida; Masahiro Tsuchida; Mine Harada
Journal:  Int J Hematol       Date:  2010-05-14       Impact factor: 2.490

3.  Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.

Authors:  Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
Journal:  Int J Hematol       Date:  2016-04-27       Impact factor: 2.490

4.  Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.

Authors:  Annalisa Paviglianiti; Erick Xavier; Annalisa Ruggeri; Patrice Ceballos; Eric Deconinck; Jan J Cornelissen; Stephanie Nguyen-Quoc; Natacha Maillard; Guillermo Sanz; Pierre-Simon Rohrlich; Laurent Garderet; Fernanda Volt; Vanderson Rocha; Nicolaus Kroeger; Eliane Gluckman; Nathalie Fegueux; Mohamad Mohty
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

Review 5.  Late Complications of Allogenic Stem Cells Transplantation in Leukaemia.

Authors:  Sharmilla Kanagasundram; Farhanaz Amini
Journal:  Tissue Eng Regen Med       Date:  2018-09-06       Impact factor: 4.169

6.  Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).

Authors:  Yong-Rong Lai; Yu-Hong Chen; Deng-Ming Hu; Ming Jiang; Qi-Fa Liu; Lin Liu; Jian Hou; Paul Schwarzenberger; Qiao-Chuan Li; Zhong-Ming Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2014-08-21       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.